Compare Global X Lithium & Battery Tech ETF (LIT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Moderna, Inc. — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.21, while Moderna, Inc. trades at $59.73 (market cap $23.60B). Which is the better fit depends on your goals.
| LIT | MRNA | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $81.80 |
52-Week Low | $40.80 | $22.36 |
Market Cap | — | $23.60B |
Enterprise Value | — | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT trades at $66.92, down 2.14% on the day, reflecting recent volatility amid shifting EV market dynamics. The ETF has doubled over the past year, driven by strong momentum in lithium, energy storage, and semiconductor sectors. Key holdings benefit from global EV sales growth, with June marking the fourth consecutive monthly increase. A dividend of $0.32 is scheduled for July 2026, providing income potential.
Outlook remains positive due to structural demand for lithium in EVs and renewables, though risks include Chinese export controls and U.S.-China trade tensions. Analyst sentiment is bullish, citing inflection in lithium markets and reshoring trends. Investors should monitor policy developments and supply chain stability for sustained gains.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
